Astrazeneca Pharma India: revenue up 30.4% to ₹729 Cr, net profit up 14.9% to ₹62 Cr
Results · Finvezto · 5 Nov 2026 · Astrazeneca Pharma India (ASTRAZEN)
Results ₹ Cr
| Latest quarter | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 729 | - | +30.4% |
| Operating profit | 96 | - | +27.1% |
| Net profit | 62 | - | +14.9% |
| Operating margin | 13.1% | - | -0.3 pp |
| Net margin | 8.5% | - | -1.2 pp |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- AstraZeneca Pharma India reported a 30% year-on-year increase in total revenue from operations to Rs 729.10 crore for the second quarter ended September 30, 2026, up from Rs 559.10 crore a year earlier. NSE filing
- Revenue was driven by oncology at Rs 508.50 crore and biopharmaceuticals at Rs 161.00 crore, alongside three new regulatory approvals secured during the quarter. NSE filing
- Revenue was ₹729 Cr, up 30.4% on a year earlier. Finvezto data
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.